CN106459998A - 预防或治疗慢性乙型肝炎病毒(hbv)感染的基于病毒样囊泡(vlv)的疫苗 - Google Patents

预防或治疗慢性乙型肝炎病毒(hbv)感染的基于病毒样囊泡(vlv)的疫苗 Download PDF

Info

Publication number
CN106459998A
CN106459998A CN201580025501.8A CN201580025501A CN106459998A CN 106459998 A CN106459998 A CN 106459998A CN 201580025501 A CN201580025501 A CN 201580025501A CN 106459998 A CN106459998 A CN 106459998A
Authority
CN
China
Prior art keywords
hbv
hepatitis
virus
antigen
vlv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580025501.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·罗贝克
J·罗斯
T·雷诺兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of CN106459998A publication Critical patent/CN106459998A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580025501.8A 2014-05-16 2015-05-11 预防或治疗慢性乙型肝炎病毒(hbv)感染的基于病毒样囊泡(vlv)的疫苗 Pending CN106459998A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461994166P 2014-05-16 2014-05-16
US61/994,166 2014-05-16
PCT/US2015/030100 WO2015175380A1 (en) 2014-05-16 2015-05-11 VIRUS LIKE VESICLES (VLVs) BASED VACCINES TO PREVENT OR TREAT CHRONIC HEPATITIS B VIRUS (HBV) INFECTION

Publications (1)

Publication Number Publication Date
CN106459998A true CN106459998A (zh) 2017-02-22

Family

ID=54480490

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580025501.8A Pending CN106459998A (zh) 2014-05-16 2015-05-11 预防或治疗慢性乙型肝炎病毒(hbv)感染的基于病毒样囊泡(vlv)的疫苗

Country Status (8)

Country Link
US (1) US9987353B2 (enExample)
EP (1) EP3143144A4 (enExample)
JP (1) JP2017515508A (enExample)
CN (1) CN106459998A (enExample)
AU (1) AU2015259470A1 (enExample)
BR (1) BR112016026721A2 (enExample)
CA (1) CA2948181A1 (enExample)
WO (1) WO2015175380A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108949790A (zh) * 2017-10-27 2018-12-07 电子科技大学 一种基于基因工程烟草的1,2,3-三氯丙烷生物降解方法
CN112513063A (zh) * 2018-05-10 2021-03-16 克莱尔博治疗有限公司 用于治疗乙型肝炎感染的方法和组合物
CN113227121A (zh) * 2018-10-05 2021-08-06 Rnagene公司 通过特异性结合至靶细胞具有增强的多种免疫功能的嵌合抗原及其用途
CN113234692A (zh) * 2021-05-11 2021-08-10 华中农业大学 一种包含狂犬病毒糖蛋白的感染性克隆及应用
CN113736750A (zh) * 2021-09-22 2021-12-03 中牧实业股份有限公司 一株盖他病毒毒株及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109154004B (zh) * 2016-01-12 2023-06-06 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） 用于治疗hbv的手段和方法
EP3276006A1 (en) * 2016-07-27 2018-01-31 Theravectys Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
CN110382009A (zh) * 2016-12-29 2019-10-25 富荣吉有限责任公司 Retro-HBV和Lenti-HBV的混合载体及构建体
EP4458975A3 (en) * 2019-09-30 2025-02-12 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
EP4087858A1 (en) 2020-01-10 2022-11-16 Carogen Corporation Compositions and methods of use of oncolytic virus like vesicles
CN113138276B (zh) * 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
WO2023133509A2 (en) * 2022-01-08 2023-07-13 Carogen Corporation Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection
WO2023164457A2 (en) * 2022-02-22 2023-08-31 Carogen Corporation Versatile virus-like-vesicles (vlv) platform for infectious diseases and cancer immunotherapy applications
CN115747174A (zh) * 2022-09-15 2023-03-07 武汉大学 重组溶瘤病毒rVSVM51R-C在乙肝性肝癌中的应用
JP2025537544A (ja) * 2022-11-07 2025-11-18 シァメン・ユニヴァーシティ 融合タンパク質及びそれを含む粒状抗原

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099932A1 (en) * 1998-05-12 2003-05-29 Lorens James B. Retroviral vectors with separation sequences
CN1872994A (zh) * 1999-12-03 2006-12-06 康斯乔最高科学研究公司 感染性克隆
CN101355960A (zh) * 2005-10-18 2009-01-28 诺华疫苗和诊断公司 使用α病毒复制子颗粒进行粘膜和全身免疫
US20100322965A1 (en) * 2008-01-11 2010-12-23 Rose John K Viral vaccine vectors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015175382A1 (en) * 2014-05-16 2015-11-19 Yale University Evolution of high-titer virus-like vesicles for vaccine applications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099932A1 (en) * 1998-05-12 2003-05-29 Lorens James B. Retroviral vectors with separation sequences
CN1872994A (zh) * 1999-12-03 2006-12-06 康斯乔最高科学研究公司 感染性克隆
CN101355960A (zh) * 2005-10-18 2009-01-28 诺华疫苗和诊断公司 使用α病毒复制子颗粒进行粘膜和全身免疫
US20100322965A1 (en) * 2008-01-11 2010-12-23 Rose John K Viral vaccine vectors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EHRENGRUBER，M.U ET AL.: ""Semliki Forest virus expression vector pSFV4(PD)，complete sequence"Accession Number：EF535150.1", 《GENBANK》 *
EVA ZUSINAITE ET AL.: ""Mutations at the palmitoylation site of non-structural protein nsP1 of Semliki Forest virus attenuate virus replication and cause accumulation of compensatory mutations"", 《JOURNAL OF GENERAL VIROLOGY》 *
K.LUNDSTROM ET AL.: ""IMPROVED SEMLIKI FOREST VIRUS VECTORS FOR RECEPTOR RESEARCH AND GENE THERAPY"", 《J. OF RECEPTOR & SIGNAL TRANSDUCTION RESEARCH》 *
MARKUS U EHRENGRUBER ET AL.: ""Semliki Forest virus vectors with mutations in the nonstructural protein 2 gene permit extended superinfection of neuronal and non-neuronal cells"", 《JOURNAL OF NEUROVIROLOGY》 *
RODRIGUEZ-MADOZ ET AL.: ""Semliki Forest Virus Vectors Engineered to Express Higher IL-12 Levels Induce Efficient Elimination of Murine Colon Adenocarcinomas"", 《MOLECULAR THERAPY》 *
梅长林: "《中国内科年鉴·2003》", 31 March 2004, 第二军医大学出版社 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108949790A (zh) * 2017-10-27 2018-12-07 电子科技大学 一种基于基因工程烟草的1,2,3-三氯丙烷生物降解方法
CN112513063A (zh) * 2018-05-10 2021-03-16 克莱尔博治疗有限公司 用于治疗乙型肝炎感染的方法和组合物
US12202862B2 (en) 2018-05-10 2025-01-21 Melbourne Health Methods and compositions for the treatment of hepatitis B infection
CN113227121A (zh) * 2018-10-05 2021-08-06 Rnagene公司 通过特异性结合至靶细胞具有增强的多种免疫功能的嵌合抗原及其用途
CN113234692A (zh) * 2021-05-11 2021-08-10 华中农业大学 一种包含狂犬病毒糖蛋白的感染性克隆及应用
CN113234692B (zh) * 2021-05-11 2022-02-22 华中农业大学 一种包含狂犬病毒糖蛋白的感染性克隆及应用
CN113736750A (zh) * 2021-09-22 2021-12-03 中牧实业股份有限公司 一株盖他病毒毒株及其应用
CN113736750B (zh) * 2021-09-22 2023-03-31 中牧实业股份有限公司 一株盖他病毒毒株及其应用

Also Published As

Publication number Publication date
AU2015259470A1 (en) 2016-11-10
JP2017515508A (ja) 2017-06-15
US20170056493A1 (en) 2017-03-02
BR112016026721A2 (pt) 2017-10-31
EP3143144A1 (en) 2017-03-22
EP3143144A4 (en) 2017-12-20
WO2015175380A1 (en) 2015-11-19
CA2948181A1 (en) 2015-11-19
US9987353B2 (en) 2018-06-05

Similar Documents

Publication Publication Date Title
US9987353B2 (en) Virus like vesicles (VLVS) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection
Barry et al. Protection against mycoplasma infection using expression-library immunization
JP6613399B2 (ja) Ｈｂｖに対する免疫応答を生じさせるために用いられるウイルス様粒子
CN106459997A (zh) 用于疫苗应用的高效价病毒样囊泡的进化
JPWO2012053646A1 (ja) ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター
US20230406889A1 (en) Live-attenuated flaviviruses with heterologous antigens
EP4205762A1 (en) Improved dna vaccine for sars-cov-2
Ying et al. Construction and immunological characterization of CD40L or GM-CSF incorporated Hantaan virus like particle
JP5710254B2 (ja) 外来エピトープを含む組換え偽ウイルスの発現および分泌を可能とするポリヌクレオチド、それらの製造および使用
JP2020537526A (ja) Ｒｓｖ抗原性タンパク質又はその断片をコードする２つの発現カセットを有するアデノウイルスベクター
US20250121052A1 (en) Sars-cov-2 vaccines
US20240181041A1 (en) Adenovirus SARS-CoV-2 Vaccine
Hong et al. Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice
Zhou et al. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine
US10160979B2 (en) Pharmaceutical composition for treatment and/or prevention of hepatitis C
KR20240004429A (ko) B형 간염 치료용 렌티바이러스 벡터, 렌티바이러스 입자, 및 그의 제조 방법 및 그의 용도
JP2011088864A (ja) インフルエンザウイルスに対するベクターワクチン
TWI906499B (zh) 一種治療ｂ型肝炎的慢病毒載體、慢病毒顆粒及其製備方法和應用
JP2022537324A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１抗体の組合せ
JP2022536850A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
Cui et al. Immunogenicity and protective efficacy of DHBV DNA vaccines expressing envelope and capsid fusion proteins in ducks delivered by attenuated Salmonella typhimurium
Nam et al. Modulation of immune response induced by co-administration of DNA vaccine encoding HBV surface antigen and HCV envelope antigen in BALB/c mice
HK40074915B (zh) 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用
WO2024026274A2 (en) Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc)
HK40074915A (en) A kind of lentiviral vector, lentiviral particle for treating hepatitis b and its preparation method and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170222

WD01 Invention patent application deemed withdrawn after publication